ESPR · As filed with the SEC
Esperion Therapeutics cash flow statement, by fiscal year
The statement as Esperion Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Statements of Cash Flows · USD thousands
| USD thousands | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||
| Net loss | — | — | — | — | — | (143,551) | (97,165) | (201,810) |
| Net loss | (22,682) | (51,745) | (209,248) | (233,659) | (269,108) | — | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Non-cash loss on extinguishment of debt and exchange transaction | 0 | 54,918 | — | 0 | (2,646) | — | — | — |
| Non-cash royalty revenue | (55,055) | (26,077) | — | — | — | — | — | — |
| Paid-in-kind interest on long-term debt | 9,093 | — | — | — | — | — | — | — |
| Non-cash interest expense related to the revenue interest liability | 0 | 21,569 | 46,679 | 44,590 | 33,907 | 19,560 | 8,120 | — |
| Non-cash interest expense related to the royalty sale liability | 57,211 | 24,657 | — | — | — | — | — | — |
| Stock-based compensation expense | 9,870 | 11,993 | 11,958 | 15,215 | 24,306 | 28,385 | 25,884 | 23,968 |
| Depreciation expense | 105 | 63 | 164 | 500 | 612 | 547 | 319 | 265 |
| Accretion and amortization of premiums and discounts on investments | 0 | 0 | (412) | 279 | 12 | (97) | (200) | (217) |
| Amortization of debt issuance costs and discounts | 3,007 | 1,498 | 1,697 | 1,621 | 1,621 | 1,741 | — | — |
| Acquired in-process research and development | — | — | — | — | 0 | 12,500 | — | — |
| Changes in assets and liabilities: | ||||||||
| Accounts receivable | (60,048) | (31,648) | (14,765) | (10,795) | (10,546) | — | — | — |
| Prepaids and other assets | (30,800) | (13,904) | 6,192 | 1,419 | 99 | (14,793) | (3,396) | (2,884) |
| Deferred revenue | 25,959 | (16,884) | 21,895 | (2,810) | 4,655 | (490) | 2,152 | — |
| Inventories | (10,633) | (28,868) | (30,422) | (807) | (18,258) | (16,136) | — | — |
| Accounts payable | — | — | — | 5,603 | (34,099) | — | — | — |
| Accounts payable | 20,918 | 12,432 | 8,678 | — | — | 23,106 | (16,055) | 24,446 |
| Other accrued liabilities | 31,223 | 18,342 | 22,097 | 4,017 | 6,926 | 2,761 | 10,000 | 7,594 |
| Other long-term liabilities | 8,739 | — | — | 0 | (1,290) | 1,290 | — | — |
| Net cash used in operating activities | (13,093) | (23,654) | (135,487) | (174,827) | (263,809) | (85,177) | (70,341) | (148,638) |
| Investing activities | ||||||||
| Purchases of investments | — | 0 | 0 | (59,897) | (50,484) | (4,420) | (34,326) | (25,481) |
| Proceeds from sales/maturities of investments | 0 | 0 | 42,500 | 68,001 | 0 | 39,145 | 99,510 | 166,081 |
| Purchases of in-process research and development | — | — | — | — | 0 | (12,500) | — | — |
| Purchases of property and equipment | 0 | (317) | — | — | 0 | (869) | (953) | (151) |
| Net cash (used in) provided by investing activities | 0 | (317) | 42,500 | 8,104 | (50,484) | 21,356 | 64,231 | 140,449 |
| Financing activities | ||||||||
| Proceeds from revenue interest liability, net of issuance costs | — | — | — | 0 | 49,917 | 25,000 | 124,424 | — |
| Payments on revenue interest liability | — | — | — | — | — | (500) | — | — |
| Proceeds from royalty sale liability | 0 | 304,656 | — | — | — | — | — | — |
| Payment of royalty sale liability issuance costs | — | (9,626) | — | — | — | — | — | — |
| Repurchase or principal payment of revenue interest liability | — | (343,750) | — | — | — | — | — | — |
| Payment of royalty sale liability issuance costs | 0 | — | — | 0 | (440) | (8,405) | — | — |
| Purchase of capped call options associated with convertible notes | — | — | — | — | 0 | (46,004) | — | — |
| Repurchase or principal payment of revenue interest liability | 0 | — | — | — | — | — | — | — |
| Payments on revenue interest liability | 0 | (5,832) | (15,506) | (8,024) | (3,389) | — | — | — |
| Payment for debt issuance costs, debt-to-equity conversion | — | — | — | — | (315) | — | — | — |
| Repayment of principal on revenue interest liability | — | — | 0 | (50,000) | — | — | — | — |
| Payment for other issuance costs | — | — | 0 | (219) | — | — | — | — |
| Proceeds from credit agreement, net of issuance costs | 0 | 145,376 | — | — | — | — | — | — |
| Proceeds from issuance of convertible notes, net of issuance costs | 0 | 99,726 | — | — | 0 | 280,000 | — | — |
| Prepayment of forward stock repurchase transaction | — | — | — | — | 0 | (55,000) | — | — |
| Repayment of convertible notes | (54,912) | (210,088) | — | — | — | — | — | — |
| Proceeds from issuance of common stock, net of issuance costs | 72,596 | 90,672 | 52,428 | 0 | 208,975 | — | — | — |
| Proceeds from issuance of common stock from ATM Program, net of issuance costs | — | 513 | 4,448 | 90,849 | 9,713 | — | — | — |
| Proceeds from exercise of common stock options | — | — | — | 0 | 3,762 | 6,634 | 11,771 | 11,743 |
| Payments on long-term debt | — | — | — | — | — | 0 | — | (1,049) |
| Proceeds from issuance of common stock from ATM Program, net of issuance costs | 15,408 | — | — | — | — | — | — | — |
| Proceeds from exercise of warrants | 10,348 | 14,808 | 9,069 | — | — | — | — | — |
| Proceeds from exercise of pre-funded warrants | — | — | 21 | — | — | — | — | — |
| Payment of issuance costs | (7,500) | — | — | — | — | — | — | — |
| Other financing activities | 244 | 29 | — | — | — | — | — | — |
| Net cash provided by financing activities | 36,184 | 86,484 | 50,460 | 32,606 | 268,223 | 201,725 | 136,195 | 10,694 |
| Net increase (decrease) in cash and cash equivalents | 23,091 | 62,513 | (42,527) | (134,117) | (46,070) | 137,904 | 130,085 | 2,505 |
| Cash, cash equivalents at beginning of period | 144,761 | 82,248 | 124,775 | 258,892 | 304,962 | 167,058 | 36,973 | 34,468 |
| Cash and cash equivalents at end of period | 167,852 | 144,761 | 82,248 | 124,775 | 258,892 | 304,962 | 167,058 | 36,973 |
| Supplemental disclosure of cash flow information: | ||||||||
| Issuance costs not yet paid | — | — | — | 1 | 269 | — | — | — |
| Issuance costs not yet paid | — | 7,500 | — | — | — | — | — | — |
| Issuance costs not yet paid | 0 | — | 635 | — | — | — | — | — |
| Purchase of property and equipment not yet paid | 189 | — | — | — | 0 | 0 | 190 | 199 |
| Non-cash right of use asset | 37 | 98 | 115 | 5 | (7) | 20 | 31 | — |
| Offering costs not yet paid | — | — | — | — | 0 | 495 | — | — |
| Other financing activities | — | 29 | — | — | — | — | — | — |
| Income taxes paid (refer to Note 17) | 612 | — | — | — | — | — | — | — |
| Cash paid for interest | 16,266 | — | — | — | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.